Featured Research

from universities, journals, and other organizations

New Molecular Marker Of Gastric Cancer

Date:
March 30, 2009
Source:
World Journal of Gastroenterology
Summary:
A research group from China investigated the prognostic significance of phosphatase regenerating liver 3 (PRL-3) in gastric cancer. They found that PRL-3 is a new independent prognostic indicator to predict the potential of recurrence and survival in patients with gastric cancer at the time of tumor resection.

Gastric cancer (GC) is one of the most common malignancies in the world with a high incidence and death rate. TNM staging system is used worldwide to predict prognosis and direct therapeutic decisions of patients with GC. However, the prognoses of patients with stage 2 and 3 GC are more heterogeneous and less predictable by staging criteria.

Therefore, finding molecular markers that are able to predict the potential of tumor recurrence and prognosis of patients is extremely important for appropriate individualized therapy.

Phosphatase regenerating liver 3 (PRL-3), a member of phosphotase of regenerating liver, has aroused broad attention in the research area of tumor metastasis. A growing body of evidence has proved PRL-3 to be an important metastatic instrumental molecule. In gastric cancer, PRL-3 was found to be highly expressed in tumor metastatic lymph nodes and closely associated with the peritoneal metastasis, but the prognostic impact of PRL-3 expression in gastric cancer still remains to be further investigated.

A research team led by Dr. Ji-You Li from Peking University University addressed this issue.

In their study, PRL-3 expression in paraffin-embedded tumor specimens from 293 patients with gastric cancer was studied retrospectively by immunohistochemistry. Monoclonal antibody specifically against PRL-3, 3B6, was obtained with hybridoma technique.

Positive PRL-3 expression was detected in 43.3% (127 of 293) of gastric cancer cases. High expression of PRL-3 was positively correlated with tumor size, depth of invasion, vascular/lymphatic invasion, lymph node metastasis, high TNM stage and tumor recurrence. Patients with positive PRL-3 expression had a significantly lower 5-year survival rate than those with negative expression (28.3% vs 51.9%, P < 0.0001). Patients who received curative surgery, and with positive PRL-3 expression had a significant shorter overall survival and disease-free disadvantage over patients with negative expression (hazard ratio of 16.7 and 16.6, respectively; P < 0.0001 for both). Multivariate analysis revealed that PRL-3 expression was an independent prognostic indicator for overall and disease-free survival of gastric cancer patients, particularly for survival in TNM stage 3 patients.

Their result indicated that PRL-3 expression is a new independent prognostic indicator to predict the potential of recurrence and survival in patients with gastric cancer at the time of tumor resection.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Dai et al. Expression of phosphatase regenerating liver 3 is an independent prognostic indicator for gastric cancer. World Journal of Gastroenterology, 2009; 15 (12): 1499 DOI: 10.3748/wjg.15.1499

Cite This Page:

World Journal of Gastroenterology. "New Molecular Marker Of Gastric Cancer." ScienceDaily. ScienceDaily, 30 March 2009. <www.sciencedaily.com/releases/2009/03/090330123215.htm>.
World Journal of Gastroenterology. (2009, March 30). New Molecular Marker Of Gastric Cancer. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2009/03/090330123215.htm
World Journal of Gastroenterology. "New Molecular Marker Of Gastric Cancer." ScienceDaily. www.sciencedaily.com/releases/2009/03/090330123215.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins